Drug Discovery & Development | UK's NICE Issues Final Appraisal Determination on CTI Lymphoma Drug Drug Discovery & Development ... reviewed CTI's updated data analysis showing Pixuvri's cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving ... PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from ... |
